Patients with high expression of RUNX3 showed better tumor regression response and down-staging compared with those with low expression of RUNX3.46 There is currently few research on EZH2 expression alterations before and after rectal cancer neoadjuvant therapy. Here, RUNX3 is linked to rectal cancer.